Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Patient Registry Software Market is Expected to Reach $8.9 billion by 2032The global patient registry software market was valued at $1.8 billion in 2022 and it is expected to reach $8.9 billion at a CAGR of 17.3% between 2023 and 2032.
The adoption of supportive government initiatives, expanding post-marketing surveillance usage of stored data, and the rising use of electronic health records are all expected to have a large positive impact on the global market for patient registry software. Throughout the forecast period, it is predicted that the patient registry software market will benefit from the major transformation that the healthcare sector is undergoing as a consequence of growing pressure to reduce costs and increase access to social media and mobile technologies. Moreover, due to their multiple clinical and non-clinical applications, electronic health records have been able to inspire attention from government sources. The governments of both developed and developing nations around the world are establishing some federal programs, initiatives, and projects to advance healthcare services. Browse the full report at https://www.sheeranalyticsandinsights.com/ On the other hand, there are some factors that could hamper the market growth in the future. For instance, Issues like unauthorized usage, intrusion, data corruption, damage, fraud, and theft are major factors restraining the growth of the patient registry software market during the projection period. On the other hand, privacy- and data security-related concerns and a shortage of educated and professional resources are likely to hamper the market's expansion. Key Players are ArborMetrix (U.S), Armus Corporation (U.S), Cedaron (U.S), Conduent (U.S), Dacima Software (Canada), ESO Solutions (U.S), Elekta (Sweden), Evado Clinical (Australia), IBM (U.S), ImageTrend (U.S), IQVIA (U.S), MecKesson Corporation (U.S), Nexus (Germany), OpenTextCorp (Canada), Phamax AG (Switzerland) End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|